[One-year therapy with dihydroergocristine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study].
This double-blind study of dihydroergocristine (DHEC, CAS 17479-19-5) versus placebo was performed in 240 elderly patients affected by chronic cerebrovascular disease or organic brain syndrome. The therapy was carried on for one year. Results pointed out a decrease of SCAG total score and a significant improvement of the target items "confusion, mental alertness and memory performance" after DHEC versus placebo. Furthermore the data show that DHEC maintained its activity throughout the 12-month trial period. Very few and mild side-effects were reported for both groups, thus confirming the well known good safety of the compound. Based on results of this 1-year investigation, it is concluded that DHEC treatment should not be abruptly interrupted, but continued for as long as possible.
Agliati
G
G
Abteilung für Innere Medizin, Krankenhaus von Vaprio, d'Adda, Mailand, Italien.
Lazzaroni
M
M
Mariani
G
G
Marras
F
F
Massetto
N
N
Menozzi
C
C
Ortenzi
E
E
Perna
G
G
Puppo
N
N
Santambrogio
S
S
D000368:Aged; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000523:psychology; D008875:Middle Aged
D004088:Dihydroergotoxine
Einjährige Therapie mit Dihydroergocristin zur Behandlung von Aufmerksamkeits- und Gedächtnisstörungen bei älteren Patienten. Plazebo-kontrollierte multizentrische Studie.